The average one-year price target for CEL-SCI (NYSEAM:CVM) has been revised to $25.50 / share. This is a decrease of 91.67% from the prior estimate of $306.00 dated July 15, 2025. The price target is ...
CEL-SCI shares are trading higher by 18.6% during Wednesday's session. The company received positive feedback from the FDA regarding their cancer immunotherapy. 9 Out of the Last 10 Summers this ...
Following the transaction, Geert R. owns 120,815 shares of the company. ・Cel-Sci is most known for its experimental cancer treatment called Multikine. ・The company is currently preparing to conduct a ...
Short interest in CEL-SCI Corp (AMEX:CVM) decreased during the last reporting period, falling from 1.04M to 766.46K. This put 11.24% of the company's publicly available shares short. Short interest in ...
As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys. At CEL ...